Comparing GLP-1 Receptor Agonists with SGLT2 Inhibitors for Type 2 Diabetes

Article

Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RA), as well as sodium-glucose co-transport 2 inhibitors (SGLT2i) have proven cardiovascular benefits in treating patients with type 2 diabetes.

However, selecting the right drug for the right treatment can be difficult.

In a study planned to be presented at the ENDO 2020, Ali Al-Khazaali, MD, Albert Stewart, MD, and Alexis McKee, of Saint Louis University, evaluated the data to aid in the prescribing decision with regard to severity of illness and risk of adverse events for patients with type 2 diabetes mellitus.

In a HCPLive® DocTalk interview, the trio of investigators discussed their study and explained what needs to happen in the future to improve patient care and reduce the risk of cardiovascular events.

Related Videos
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.